drugset / Trial / NCT00448786

Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors

NCT00448786

Phase 1 Completed 49 enrolled Amgen
RandomizedCrossoverOpen-labelTreatment

Summary

The study involves the use of three different dosing regimens of AMG 706 in patients with advanced solid tumors to see how the drug affects the gallbladder size and function. The study will be conducted in 11 sites in the US and Australia. A total of 48 patients will be enrolled in the study with the possibility of enrolling 8 more in each treatment arm.

Timeline

Start
2007-02
Primary completion
2008-12
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject motesanib Small molecule 75 mg Oral
Subject motesanib Small molecule 125 mg Oral

Indications